Home / Superinvestors / Baupost Group
Baupost Group
Value
$7.598B
Positions
42
Top 10 weight
72.4%
Holdings
42 stocks| Stock | Shares | Value ▲ | Reported Price | Current Price | vs Reported | 52W | Weight |
|---|---|---|---|---|---|---|---|
| SABAN CAP ACQUISITION CORP | 1,163,250 | $1.105M | $0.95 | - | - | - | 0.0% |
| CONYERS PK ACQUISITION | 1,237,500 | $2.475M | $2.00 | - | - | - | 0.0% |
| OREXIGEN THERAPEUTICS INC | 2,226,839 | $3.875M | $1.74 | - | - | - | 0.1% |
| TRILOGY METALS INC NEW | 10,600,758 | $5.339M | $0.50 | $1.94 | +285.2% | $1.94 – $6.89 | 0.1% |
| CITIGROUP INC | 62,903,207 | $9.561M | $0.15 | - | - | - | 0.1% |
| SUNRUN INC | 2,848,082 | $15.12M | $5.31 | $8.63 | +62.5% | $6.89 – $21.41 | 0.2% |
| Liberty Expedia Holdings, Inc. | 395,613 | $15.69M | $39.67 | - | - | - | 0.2% |
| LIBERTY MEDIA CORP DELAWARE | 800,000 | $16.39M | $20.49 | - | - | - | 0.2% |
| CASCADIAN THERAPEUTICS INC | 4,166,666 | $17.96M | $4.31 | - | - | - | 0.2% |
| SABAN CAP ACQUISITION CORP | 2,326,500 | $23.27M | $10.00 | - | - | - | 0.3% |
| PARATEK PHARMACEUTICALS INC | 2,044,498 | $31.49M | $15.40 | - | - | - | 0.4% |
| CONYERS PK ACQUISITION | 3,712,500 | $37.98M | $10.23 | - | - | - | 0.5% |
| CENCORA INC | 502,474 | $39.29M | $78.19 | $359.03 | +359.2% | $252.74 – $374.75 | 0.5% |
| NOVAGOLD RES INC | 9,500,000 | $43.32M | $4.56 | $5.63 | +23.5% | $5.18 – $14.20 | 0.6% |
| CENTENNIAL RESOURCE DEV INC | 2,407,153 | $43.57M | $18.10 | - | - | - | 0.6% |
| GTY TECHNOLOGY HOLDINGS INC | 4,400,000 | $46.2M | $10.50 | - | - | - | 0.6% |
| CHIPMOS TECHNOLOGIES INC | 3,509,858 | $49.52M | $14.11 | - | - | - | 0.7% |
| CREDIT ACCEP CORP MICH | 244,400 | $53.16M | $217.51 | $504.63 | +132.0% | $411.04 – $657.20 | 0.7% |
| Liberty Interactive, Liberty Ventures, Series A | 1,481,719 | $54.63M | $36.87 | - | - | - | 0.7% |
| SYNGENTA AG | 745,136 | $58.9M | $79.05 | - | - | - | 0.8% |
| AMERICAN INTL GROUP INC | 2,594,317 | $60.86M | $23.46 | - | - | - | 0.8% |
| LIBERTY MEDIA CORP DELAWARE | 2,994,010 | $61.65M | $20.59 | - | - | - | 0.8% |
| CARDINAL HEALTH INC | 1,030,000 | $74.13M | $71.97 | $281.10 | +290.6% | $182.50 – $281.10 | 1.0% |
| ATARA BIOTHERAPEUTICS INC | 5,359,632 | $76.11M | $14.20 | - | - | - | 1.0% |
| FORWARD PHARMA A/S | 5,367,300 | $80.51M | $15.00 | - | - | - | 1.1% |
| MCKESSON CORP | 1,000,000 | $140.5M | $140.45 | $1,102.81 | +685.2% | $725.17 – $1,102.81 | 1.8% |
| COLONY CAP INC | 6,959,017 | $140.9M | $20.25 | - | - | - | 1.9% |
| KERYX BIOPHARMACEUTICALS INC | 25,791,678 | $151.1M | $5.86 | - | - | - | 2.0% |
| INNOVIVA INC | 14,931,483 | $159.8M | $10.70 | $19.03 | +77.9% | $18.86 – $24.24 | 2.1% |
| VERITIV CORP | 3,044,385 | $163.6M | $53.75 | - | - | - | 2.2% |
| TWENTY FIRST CENTY FOX INC | 7,278,100 | $198.3M | $27.25 | - | - | - | 2.6% |
| NORTHSTAR RLTY FIN CORP | 14,577,134 | $220.8M | $15.15 | - | - | - | 2.9% |
| NORTHSTAR ASSET MGMT GROUP I | 18,705,000 | $279.1M | $14.92 | - | - | - | 3.7% |
| THERAVANCE BIOPHARMA INC | 9,273,991 | $295.7M | $31.88 | - | - | - | 3.9% |
| ANTERO RESOURCES CORP | 14,505,881 | $343.1M | $23.65 | $38.74 | +63.8% | $31.38 – $45.15 | 4.5% |
| Dell Technologies Inc Class V | 6,652,459 | $365.7M | $54.97 | - | - | - | 4.8% |
| PBF ENERGY INC | 15,724,175 | $438.4M | $27.88 | $71.28 | +155.7% | $26.02 – $91.17 | 5.8% |
| NEWS CORP | 19,137,469 | $536.6M | $28.04 | - | - | - | 7.1% |
| ALLERGAN PLC | 3,432,603 | $720.9M | $210.01 | - | - | - | 9.5% |
| SYNCHRONY FINANCIAL | 20,665,000 | $749.5M | $36.27 | $72.25 | +99.2% | $63.78 – $88.47 | 9.9% |
| VIASAT INC | 13,158,137 | $871.3M | $66.22 | $67.72 | +2.3% | $30.35 – $89.81 | 11.5% |
| CHENIERE ENERGY INC | 21,726,340 | $900.1M | $41.43 | $308.75 | +645.2% | $188.83 – $330.32 | 11.8% |
Combines 44 filed positions into 42 CUSIPs. Positions split across delegated managers are summed.
13F reports long positions only (including long options; shorts and cash excluded) as of quarter end.
Other reported positions
2 items| Stock | Type | Amount / Par | Value |
|---|---|---|---|
| THERAVANCE INC | Principal (bond/note) | 46,230,000 | $38.37M |
| THERAVANCE BIOPHARMA INC | Principal (bond/note) | 30,000,000 | $34.06M |
Bonds, notes, preferred/depositary shares, zero-value positions and options (call/put) are listed for completeness but are not counted in the value or position totals — shares only, value above zero, options excluded, preferred excluded (the Dataroma convention). Options are shown as the underlying share count and its value, not as contracts.